Connect With West Coast Oncology Leaders Making Preclinical Investment Decisions
As organizations face increasing pressure to justify development spending, improve translational success, and make smarter portfolio decisions; evaluating tumor models, translational platforms, and external partners has become increasingly strategic.
The 11th Tumor Models Summit San Francisco provides direct access to the decision-makers responsible for evaluating technologies, selecting external partners, and determining how evidence is generated across oncology development programs.
Attendees include CSOs, VPs, Heads, and Directors responsible for discovery, biology, pharmacology, translational research, preclinical development, bioinformatics, and data science. These are the stakeholders influencing model selection, outsourcing strategies, technology adoption, and progression decisions across oncology pipelines.
What to Expect at the Tumor Models Summit San Francisco
Reach Decision-Makers, Not Just End Users
Meet the stakeholders responsible for evaluating technologies, selecting vendors, approving budgets, and shaping development strategy across oncology organizations.
Join Strategic Development Conversations
Position your organization within discussions focused on translational confidence, candidate prioritization, resistance modeling, biomarker development, and portfolio strategy.
Gain Insight into Emerging Priorities
Understand how oncology leaders are approaching evidence generation, model evaluation, development efficiency, and clinical predictability across different modalities.
Build Relationships Before Vendor Selection Decisions Are Finalized
Engage with teams earlier in the development lifecycle as they evaluate future technologies, platforms, and external partnerships.
Key Services & Solutions
Our attendees are actively evaluating technologies and partners that can help improve development decisions, strengthen translational confidence, and generate more predictive evidence.
Areas of Interest Include:
- In Vivo Tumor Models
- Organoid & 3D Tumor Models
- Ex Vivo & Human Tissue Platforms
- Patient-Derived Models (PDX/PDO)
- AI-Enabled Drug Discovery & Computational Modeling
- Biomarker & Translational Research Services
- Preclinical CRO & Pharmacology Services
- Sequencing, Genomics & Multi-Omics Platforms
Hear What Our Past Sponsors Have to Say
The narrow focus of TM conferences provides a great forum for the exchange of ideas and actionable conversations
Chief Marketing Officer, Certis Oncology Solutions
The small gathering of scientists working in the same field is a great place to connect to discuss problems, concerns and ways to overcome them
Senior Director - Scientific Engagement, Crown Bioscience
The discussion and interactions with other attendees were very productive.
Scientific Account manager, GenOway
Tumor Models is relevant to the people in the field of searching the right models for preclinical research. It also provides a good platform for potential customers and industry leaders for service providers to explore
Business Development Manager, GemPharmatech
Attending Companies Included
Available Inventory
Get in Touch
Take advantage of our bespoke sponsorship opportunities to achieve your commercial goals. Email us if you would like to get involved and discuss a bespoke package suited to your needs.
Damola Adejuwon
Partnerships Director
Demonstrate Real Impact on Oncology Development
Show how your solutions help teams generate stronger evidence, improve translational confidence, and make more informed development decisions.
Access the West Coast's Most Focused Preclinical Oncology Community
Connect with the leaders responsible for discovery, translational research, preclinical strategy, and portfolio progression across biotech and pharma.
Align Your Brand with Better Decision-Making
Position your organization at the center of the conversations shaping how oncology assets are evaluated, prioritized, and advanced toward the clinic.